The Question

Close-up of a neural implant chip next to a coin for scale in a research laboratory

In January 2024, Neuralink — the neurotechnology company founded by Elon Musk — implanted its N1 chip in Noland Arbaugh, then 29, who had been paralysed from the shoulders down after a diving accident. Within weeks he was controlling a computer cursor with his thoughts, playing online chess and video games for hours at a time.

Media attention focused on Musk's vision of human-computer symbiosis. Less well covered: Arbaugh was far from the first person with a brain-computer interface, or BCI. The BrainGate research consortium has run human trials of implanted BCIs since 2004, and the Utah array made by Blackrock Neurotech has been implanted in dozens of research participants. Neuralink brought a smaller, fully implanted, wireless device and far more publicity. The question now is when these devices move from research trials to approved, routine medical treatment.

What the Evidence Shows

BCIs record the electrical activity of neurons. The motor cortex produces distinctive patterns when a person intends to move — patterns that remain even when the spinal cord can no longer carry the signal. A BCI records those signals and uses machine learning, trained on the person's own brain activity, to translate them into a cursor movement, a robotic arm command or text.

The milestones have come steadily. In 2012, BrainGate researchers reported that Cathy Hutchinson, paralysed for about 15 years by a brainstem stroke, used a robotic arm controlled by her implant to lift a bottle and sip coffee. In 2021, a Stanford team reported that a man with paralysis could write 90 characters per minute by imagining handwriting, with about 94% accuracy. In 2024, UC Davis researchers reported in the New England Journal of Medicine that a man with ALS could speak through a BCI that turned his brain signals into words with up to 97% accuracy.

"We've learned that the brain retains its ability to prescribe fine movements a full decade after the body has lost its ability to execute those movements."

— Frank Willett, lead author of the Stanford handwriting BCI study, Stanford Medicine, May 2021

Neuralink's N1 implant carries 1,024 electrodes on 64 flexible threads, is fully sealed under the skull and charges wirelessly. It has had problems: in the weeks after Arbaugh's surgery, many of the threads retracted from his brain, reducing the number of working electrodes. Neuralink said software changes restored and then exceeded his earlier performance. The company has since implanted more participants in several countries and received FDA "breakthrough device" designations for a speech-restoration implant and for Blindsight, a device intended to restore some vision.

Other approaches avoid open brain surgery. Synchron's Stentrode is threaded up through the jugular vein into a blood vessel beside the motor cortex. In its US COMMAND study, all six patients met the primary safety endpoint, with no device-related serious adverse events causing death or permanent disability over a year. Precision Neuroscience received FDA clearance in 2025 for a thin electrode film that sits on the brain's surface for up to 30 days, and Paradromics received FDA approval in late 2025 to begin a first clinical study of its implant for speech.

The question is no longer whether brains and computers can be connected. It is how quickly that connection becomes a routine treatment.

Why This Is Happening

Computing has caught up with neuroscience. Decoding the activity of hundreds of neurons in real time takes a lot of computation. Advances in machine learning over the past decade have produced decoders far more accurate than were possible in 2010, and they improve as they learn from each patient's own data.

The medical need is large. According to the Christopher & Dana Reeve Foundation, about 5.4 million Americans — nearly 1 in 50 — live with some form of paralysis. Worldwide, millions more have ALS, stroke, spinal cord injury or locked-in syndrome. Few of them have good options for communication or control, which has drawn large investments into Neuralink, Synchron, Precision and others.

The path to approval is long. Implanted devices must prove safety and benefit in pivotal trials before the FDA will approve them for sale. Synchron is preparing for such a trial, but recruiting patients, following them for months or years and then winning approval and insurance coverage takes time. Cochlear implants, the closest comparison, took years to grow from first approval to widespread use.


What Could Happen

The first BCI is approved around 2030, but use grows slowly Most likely

One or more companies complete pivotal trials and win FDA approval for paralysis or speech loss in the late 2020s or early 2030s. Implantation is limited to specialist centres, insurance coverage is patchy, and by 2032 patients number in the hundreds rather than thousands.

Thousands of patients have approved, wireless implants by 2032 Possible

Pivotal trials succeed quickly, regulators move fast, and insurers agree to pay. An approved, fully implanted BCI becomes a standard option for severe paralysis at major hospitals, and thousands of people receive one by 2032.

Safety or security problems delay approvals Less likely

A serious device failure, long-term safety concern or demonstrated cyberattack on a wireless implant prompts regulators to slow approvals and demand new standards. Medical BCIs still arrive, but years later.

Our Assessment
We assign 20% probability — unlikely that a commercially approved, wireless BCI for motor restoration is in the hands of thousands of patients by 2032. We have lowered this forecast from 57%: as of 2026 no implanted BCI has full FDA approval, the leading candidate is only now preparing its pivotal trial, and approved implants typically take years to reach large numbers of patients. The science is proven: people with paralysis are already typing, speaking and controlling computers through implants in trials. The bottlenecks are regulatory timelines, surgical capacity, long-term safety data and insurance coverage.

What Can We Do

Neuroscientist analysing brain activity data on multiple computer screens

The connection of brains and computers raises questions that medical device rules were never designed to answer. Society's thinking still lags the technology.

Develop rules for BCIs before commercial products arrive. A device that reads neural signals, learns from them, connects wirelessly and sits inside the body for decades raises particular questions — about cybersecurity, software updates and what happens if a company stops supporting an implant. Regulators should address them now.

Establish clear rights over neural data. The signals a BCI records are among the most intimate data a person can generate. Who owns them? Can a manufacturer train its algorithms on them, sell them or be forced to hand them over? A few US states, including Colorado and California, have begun extending privacy law to neural data; others have not.

Fund independent long-term safety research. Much of today's BCI safety data comes from the companies developing the devices. Independent studies of what happens to brain tissue and signal quality around implants over many years are essential.

Start the public conversation about enhancement. Today's BCIs are medical devices for people with severe disabilities. If they are ever offered to healthy people to enhance memory or attention, the decision should come through public debate and regulation, not by default.